Provided by Tiger Trade Technology Pte. Ltd.

Dianthus Therapeutics Inc.

88.21
-0.1100-0.12%
Post-market: 88.210.00000.00%19:30 EDT
Volume:751.39K
Turnover:67.06M
Market Cap:4.93B
PE:-21.45
High:91.24
Open:89.05
Low:87.73
Close:88.32
52wk High:117.88
52wk Low:32.22
Shares:55.93M
Float Shares:55.85M
Volume Ratio:0.94
T/O Rate:1.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1130
EPS(LYR):-4.2037
ROE:-26.07%
ROA:-17.69%
PB:4.21
PE(LYR):-20.98

Loading ...

Dianthus Therapeutics CEO Marino Garcia Reports Disposal of 166,000 Common Shares Worth $17.97 Million

Reuters
·
Aug 08

Viridian Therapeutics Q2 Net Loss Widens as Lumvoa Launch Lifts Costs

Reuters
·
Aug 06

Climb Bio Q2 Net Loss Widens on Pipeline Advancement

Reuters
·
Aug 06

Dianthus Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $158 from $130

THOMSON REUTERS
·
Aug 06

U.S. Research Roundup-Caterpillar, Eli Lilly, McKesson

Reuters
·
Aug 06

Dianthus Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Arcus Biosciences Q2 Revenue Falls Sharply on Lower License Income

Reuters
·
Aug 06

Enliven Therapeutics Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 06

Black Diamond Therapeutics Q2 Net Loss Narrows Year over Year

Reuters
·
Aug 06

EyePoint Pharmaceuticals Q2 Revenue Drops on Lower License Income

Reuters
·
Aug 05

Seres Therapeutics Q2 Net Income Turns Positive on VOWST Sale Gain

Reuters
·
Aug 05

Analysts Conflicted on These Healthcare Names: Dianthus Therapeutics (DNTH) and American Well (AMWL)

TIPRANKS
·
Aug 05

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Viridian Therapeutics (VRDN)

TIPRANKS
·
Aug 05

Dianthus Therapeutics Q2 Net Loss Widens as R&D Costs Rise

Reuters
·
Aug 05

Dianthus Therapeutics - Reports $1.20 Bln Cash as of June 30, 2026, Provides Expected Runway into 2030

THOMSON REUTERS
·
Aug 05

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results

THOMSON REUTERS
·
Aug 05

Dianthus Therapeutics Inc Q2 Operating Expenses USD 62.243 Million

THOMSON REUTERS
·
Aug 05

Dianthus Therapeutics - Dnth312 Expected to be Phase 1 Ready by Year-End 2027

THOMSON REUTERS
·
Aug 04

Dianthus Therapeutics - Dnth312 Targets Inhibition of Ac1s and Baff/April Pathways for Autoimmune Diseases

THOMSON REUTERS
·
Aug 04

Dianthus Therapeutics - Dnth312 Demonstrates Similar Immunoglobulin Reductions to Povetacicept in Nhps

THOMSON REUTERS
·
Aug 04